MMIT Reality Check on Kidney Cancer (July 2021)

According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for kidney cancer treatments shows that under the pharmacy benefit, about 52% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In March 2021, the FDA approved Aveo Oncology’s Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma who have received at least two prior systemic therapies.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-reality-check-hemophilia.jpg
October 15

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/wordpress-featured-image-reality-check-diffuse-large-b-cell-lymphoma.jpg
October 8

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image_Pulse-Check_MS.jpg
October 1

MMIT Reality Check on Multiple Sclerosis (Oct 2021)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today